drugset / Trial / NCT04459598
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
Timeline
- Start
- 2020-08-19
- Primary completion
- 2020-10-14
- Completion
- 2020-10-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Quizartinib | Small molecule | 60 mg | Oral |
Indications
No indication recorded.